We present the case of a 47-year-old male who underwent treatment with Dupilumab 300 mg every two weeks who developed after six months' treatment a rare cutaneous reaction such as a long-lasting cutaneous reaction at the site of dupilumab subcutaneous injection together with eosinophilia; the patient has been switched, after a 2-month wash out period, to benralizumab 30 mg since without developing adverse reactions

Dupilumab‐Associated, Long-Lasting, Late-Onset, Large Local Reaction at the Injection Site in a Patient Treated for T2 Severe Asthma: A Case Report

Luca Gammeri;Marta Liotta;Edoardo Spina;Luisa Ricciardi
2023-01-01

Abstract

We present the case of a 47-year-old male who underwent treatment with Dupilumab 300 mg every two weeks who developed after six months' treatment a rare cutaneous reaction such as a long-lasting cutaneous reaction at the site of dupilumab subcutaneous injection together with eosinophilia; the patient has been switched, after a 2-month wash out period, to benralizumab 30 mg since without developing adverse reactions
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11570/3282182
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact